Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pfizer Inc. is conducting a study titled ‘Retrospective Cohort Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy.’ The study aims to assess the risk of pregnancy and infant outcomes in women with migraines who are exposed to rimegepant during pregnancy compared to two unexposed groups. This research is significant as it seeks to provide insights into the safety of rimegepant, a drug used for migraine treatment, during pregnancy.
The intervention being tested is the drug Rimegepant, administered at 75mg, which is intended to treat migraines. The study also includes comparator groups exposed to other migraine medications and a group without migraine exposure.
This observational study employs a cohort model with a retrospective time perspective. It does not involve random allocation or masking, focusing on understanding the outcomes associated with rimegepant exposure during pregnancy.
The study began on December 15, 2021, and is currently recruiting participants. The last update was submitted on July 8, 2025, indicating ongoing progress. These dates are crucial for tracking the study’s development and eventual results.
The outcome of this study could influence Pfizer’s stock performance as it may affect the perception of rimegepant’s safety profile. Positive results could enhance investor confidence, while negative findings might benefit competitors offering alternative migraine treatments.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.